Oncternal Therapeutics to Present Interim Data from a Phase 1/2 Study of Cirmtuzumab in Combination with Ibrutinib at the 2019 American Society of Clinical Oncology Annual Meeting

World News: . []

SAN DIEGO May 15 2019 GLOBE NEWSWIRE -- Oncternal Therapeutics Inc a clinical-stage biotechnology LINK  focused on developing potential first-in-class therapeutic candidates for LINK  with critical unmet medical need today LINK  th at it w...

More news and information about Oncternal Therapeutics

Published By:

Globe Newswire: 22:01 GMT Wednesday 15th May 2019

Published: .

Search for other references to "oncternal" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us